A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)
Status:
Terminated
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
Normal healthy volunteer (NHV) participants will enroll sequentially into a total of 6
escalating dose levels (6 subjects per dose level), randomized to receive a single dose of
ARC-521 Injection or placebo. The maximum study duration for NHVs is approximately 21 weeks.
Hepatitis B e Antigen (HBeAg)-negative participants with (CHB) will enroll sequentially into
3 dose levels (8 patients per dose level) to receive multiple doses of open label ARC-521
Injection. For each CHB participant the maximum study duration is approximately 37 weeks.